comprehensive -WSS

comprehensive

author：knowledge 2025-09-27 19:50:34 - browse：65925

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Pumping milk in bathrooms at health conferences is common

hotspot

focus

WSS

A pediatrician calls for Congress to pass the child tax credit deal

White House drug shortages task force keeps mum with Congress

Who are the detained American citizens released from prison in Iran?

TB outbreak tied to bone grafts underscores testing shortcomings

HPV vaccine, cervical cancer study delivers historic results

White House drug shortages task force keeps mum with Congress

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Affirmative action in medical school literally saved lives

Novo acquires Inversago for up to $1 billion

Anesthesiologist group: stop taking Ozempic before surgery

Novo acquires Inversago for up to $1 billion

Wildfire smoke exposes gaps in outdoor worker protections

Newly revealed memo details efforts to keep Trump in power following election loss

Continuity nursing helped my family in our darkest PICU moments

TB outbreak tied to bone grafts underscores testing shortcomings

The high cost of giving birth even with insurance

Cardiologists urge adding sexual orientation, gender identity to health records

entertainment

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Target recalls 2.2 million additional candles due to laceration, burn hazards

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

An innovative path out of biotech’s “valley of death”

Cardiologists urge adding sexual orientation, gender identity to health records

Kim Kardashian sparks debate on benefits of full

focus

hotspot

focus

knowledge